RealFeedApp New drug failed to reduce heart attack deaths
The ZEUS study found that ziltivekimab reduced interleukin-6 levels without decreasing heart attacks, strokes, or deaths. Novo Nordisk halted two additional trials, yet cardiologists plan to pursue anti-inflammatories for cardiovascular and metabolic disease.
- Field
- drugs and trials
- What they did
- Researchers demonstrated that an experimental drug reduced inflammation markers but failed to prevent heart attacks, strokes, or death in patients with severe illness.
- Why it matters
- This is important for cardiologists because the results help explain why some drugs lower inflammation markers without providing clinical benefit in real patients.
#inflammation#cardiovascular disease#ziltivekimab#zeus#interleukin-6#clinical trial
